Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24645260 | 0.85 | HTRA1 (0.43) | HTRA1GPR119UCHL1POLBCYP1A2 | |
| SCHEMBL24645474 | 0.83 | GPR119 (0.43) | HTRA1GPR119UCHL1USP30POLB | |
| SCHEMBL26579492 | 0.82 | SRC (0.48) | GPR119USP30RIPK1GRM5SRC | |
| SCHEMBL26579494 | 0.82 | SRC (0.48) | GPR119USP30RIPK1GRM5SRC | |
| SCHEMBL30571562 | 0.82 | SRC (0.48) | GPR119USP30RIPK1GRM5SRC | |
| SCHEMBL30571971 | 0.82 | SRC (0.48) | GPR119USP30RIPK1GRM5SRC | |
| SCHEMBL5201925 | 0.82 | HTRA1 (0.60) | HTRA1GPR119UCHL1POLBCYP1A2 | |
| SCHEMBL4195796 | 0.82 | HTRA1 (0.60) | HTRA1GPR119UCHL1POLBCYP1A2 | |
| SCHEMBL205497 | 0.82 | HTRA1 (0.60) | HTRA1GPR119UCHL1POLBCYP1A2 | |
| SCHEMBL9543379 | 0.82 | HTRA1 (0.60) | HTRA1GPR119UCHL1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | HTRA1 129/4885GPR119 4204/4885UCHL1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.